Andrew Barnhill

Chief Policy Officer in BioPharma l @NYUWagner Faculty l Former Fed Policy Director @GSK

[Andrew Barnhill @ATBarnhill]

@BobbyBorkIII Looks good!

[The Extreme Music Enthusiast @TheExtremeMusi1]

On July 4th every year, the Boston Pops Orchestra performs Tchaikovsky’s “1812 Overture” with real cannons, as the composer did in 1882.

[Library of Congress @librarycongress]

Happy Independence Day from the Library of Congress. ❤️🤍💙🇺🇸

[Jake Auchincloss @JakeAuch]

Happy 250th anniversary to the United States and “the cause of all mankind.”

[Alexander Stubb @alexstubb]

I wish to extend our warm congratulations to the people of the United States on the 250th anniversary of the Declaration of Independence.

As a young student at Furman Unversity I remember reading the Federalist Paper and the Declaration of Independence.

”We hold these truths to be self-evident, that all men are created equal, that they are endowed by their Creator with certain unalienable Rights, that among these are Life, Liberty and the pursuit of Happiness.”

Finland's ties to the United States reach back to its founding. Among the signers of the Declaration was John Morton, a Founding Father who is remembered for being of Finnish descent.

The United States and the Federalist Papers have played an important role in laying the foundation for constitutional democracies across the world.

Today as friends and allies our countries work together more closely than ever. Finland looks forward to the next 250 years of friendship and partnership.

[Andrew Barnhill @ATBarnhill]

Huge loss of a significant Member. Her influence on Cures will be a lasting contribution.

[David Lim @davidalim]

Loss by Rep. Diana DeGette in this primary is noteworthy for health care issues moving forward.

DeGette was one of the primary Democrats behind the 2016 21st Century Cures Act.

She is currently the Ranking Member of the House Energy and Commerce Health Subcommittee.

[Michael Girdley @girdley]

I know people hate this fact but:

There's a strong correlation between accomplished people and how quickly they respond to email.

[Matthew Yglesias @mattyglesias]

I think the path forward is to recognize that the battle was already lost some time in the 2016-2021 period, become less invested in propping up an "establishment" that no longer knows how to stand up for old-fashioned common sense values, and work on building the next thing.

[Biotechnology Innovation Organization @IAmBiotech]

Patrick Wildman, Senior Vice President of Advocacy & Government Relations at the @LupusOrg, spoke on the importance of keeping patients at the center of the 340B reform debate.

The session also featured Ashley John, Director of Issue Advocacy at @Novartis; Rory Martin, PhD, Senior Principal, Market Access Center of Excellence at @IQVIA_global; and Darshana Patel, PhD, Assembly Member for District 76 of the California State Assembly.

[Biotechnology Innovation Organization @IAmBiotech]

As we closed out Day 3, there were no signs of slowing down. Welcome to Day 4 - the final lap of #BIO2026!

[Biotechnology Innovation Organization @IAmBiotech]

Yesterday we caught up with Fritz Bittenbender, Senior Vice President of Public Affairs and Access at @genentech, to reflect on how far the industry has come - and where it must go next. Fritz shared why #BIO2026 marks a critical moment for biotech: an industry at its 50-year milestone, but also at a true inflection point. The policy and investment environment that once fueled breakthrough innovation isn’t guaranteed - and the choices made now will determine the next generation of progress.

Drawing from the session, “The Innovation Mandate: Strengthening the Biopharma Ecosystem for the Next Generation,” Fritz outlined what it will take to sustain U.S. leadership - from reinforcing the conditions that enabled early pioneers to ensuring today’s ecosystem can continue to deliver for patients.

In yesterday's session, Fritz was joined by the Honorable Tina Kotek - Governor of Oregon; Erin Trish, PhD, Co-Director of the @USCSchaeffer Institute; and Andrew L., Managing Director and Head of Biotech Private Equity at the Ally Bridge Group. The session was moderated by Max Bayer, Reporter for @endpts.

Read more on https://t.co/ZpbgpvzkpL: https://t.co/8TW1gO6HlQ

[Robby Soave @robbysoave]

This is an important point that actually undercuts an idea popular with some conservatives, especially Stephen Miller, that the radical left takeover is a result of importing the third world. High income, elite educated whites are more in favor of Chevalier than poorer blacks and Hispanics.

[Josh Kraushaar @JoshKraushaar]

Rep. Dan Goldman (D-NY), in concession speech: “Jews have given back so much to this country. As history has taught us, antisemitic tropes and stereotypes, some of which I heard personally on this campaign, will ultimately be the undoing of our democracy if we all don’t lean in and speak out — even if it’s not politically expedient.”

[Matthew Yglesias @mattyglesias]

In a world where local media has withered but tons of national figures live in New York, the outsized attention to everything that happens in NYC or that NYC residents care about a lot is really striking.

[HHS @HHSGov]

This week, HHS held a Clinical Trials Roundtable to announce a coordinated department-wide effort to strengthen America’s leadership in clinical research, accelerate the development of lifesaving treatments, and ensure that patients have access to the most innovative therapies in the world.

The Department’s actions reflect a broader commitment to advancing American scientific leadership, expanding patient access to cutting-edge treatments, and ensuring that the United States remains the world leader in medical innovation.

[HHS @HHSGov]

Today, HHS launched a department-wide effort to restore U.S. leadership in clinical trials by reducing unnecessary barriers, accelerating research, expanding patient access to studies, and strengthening America’s biomedical innovation ecosystem.

From FDA and NIH to ARPA-H and ONC, HHS is working to help bring more clinical research, investment, and medical breakthroughs back to the United States.

Read More:

https://t.co/1HPNxBYRWj

[Andrew Barnhill @ATBarnhill]

An eventful day at HHS today with colleagues for the launch of Operation Trial Blazer. Glad to be one of the only companies helping drive this new policy for clinical research.

[Damian Garde @damiangarde]

FDA to launch pilot program to speed up early-stage clinical trials https://t.co/e8lNUOGtK7

[Andrew Barnhill @ATBarnhill]

“We challenged ourselves to find a better way.” Today, @US_FDA established a new rolling Phase 1 submission process. A great opportunity to address speed in the process of IND submission. #hhs